Skip to main content
Clinical Trials/NCT01783184
NCT01783184
Completed
Not Applicable

Study of Abdominal Aortic Stent Grafts in the Treatment of Infrarenal Abdo Minal Aortic Aneurysms

Vascutek Ltd.24 sites in 1 country180 target enrollmentJune 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Abdominal Aortic Aneurysm
Sponsor
Vascutek Ltd.
Enrollment
180
Locations
24
Primary Endpoint
Change in diameter of the aneurysm
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The Vascutek Anaconda™ Stent Graft System for repair of Abdominal Aortic Aneurysms (AAA) is the subject of this observational study. 180 patients will be implanted with the Anaconda™ Stent Graft System and will be followed-up annually for 5 years post-implant. The study will satisfy the requirements of the French National Authority for Health (Haute Autorité de santé) and the data collected will be used for reimbursement renewal.

Detailed Description

Infrarenal abdominal aortic aneurysms may be treated with the introduction of an abdominal aortic stent graft via the femoral route. This technique is commonly used in high surgical risk patients but can also be suitable under certain conditions for normal risk patients. Abdominal aortic stent grafts, inserted via the femoral artery, are used to treat infrarenal abdominal aortic aneurysms, removing the need for an invasive surgical procedure. The aim of this observational study is to evaluate the long-term (5 year) benefits of the technique by documenting the overall mortality, complications (endoleak, migration), rate of surgical conversion, progression and rupture of the aneurysm in a cohort of patients who are representative of the treated population under real conditions of use.

Registry
clinicaltrials.gov
Start Date
June 2012
End Date
December 2019
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Vascutek Ltd.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Any patient implanted with the Vascutek Anaconda™ Stent Graft System for the treatment of a non-ruptured infrarenal Abdominal Aortic Aneurysm (AAA)

Exclusion Criteria

  • Patients for whom clinical follow-up is impossible and cannot return for check-up visits

Outcomes

Primary Outcomes

Change in diameter of the aneurysm

Time Frame: Post-op (within 30 days), 6 months, 12 months and then annually up to 5 years

Overall mortality rate

Time Frame: Post-op (within 30 days), 6 months, 12 months and then annually up to 5 years

Mortality rate related to rupture of the aneurysm and relationship to the stent

Time Frame: Post-op (within 30 days), 6 months, 12 months and then annually up to 5 years

Surgical conversion rate

Time Frame: Post-op (within 30 days), 6 months, 12 months and then annually up to 5 years

Rate of endovascular or surgical revisions

Time Frame: Post-op (within 30 days), 6 months, 12 months and then annually up to 5 years

Rate of Type I, II and III endoleaks

Time Frame: Post-op (within 30 days), 6 months, 12 months and then annually up to 5 years

Study Sites (24)

Loading locations...

Similar Trials